A Phase I/II Study of Veliparib (ABT-888) Given with Radiation Therapy and then Given with Temozolomide in Children with Newly Diagnosed Diffuse Pontine Glioma

Full Title

PBTC-033 A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)


Diffuse pontine glioma is a type of brain stem cancer most often diagnosed in children. It is very challenging to treat successfully. Doctors are therefore seeking more effective therapies.

Radiation therapy is a common part of brain tumor treatment. Temozolomide is used to treat adult brain cancers. In this study, researchers want to find the highest dose of an investigational drug called veliparib (ABT-888) that can be given safely with radiation therapy and then with temozolomide in children who are newly diagnosed with diffuse pontine glioma.

Veliparib kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells caused by treatment and possibly making them more susceptible to anticancer therapies, such as temozolomide and radiation. Veliparib and temozolomide are both taken orally (by mouth).

This study is being conducted by the Pediatric Brain Tumor Consortium, a collaboration among U.S. centers dedicated to improving the care of children with brain tumors.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have diffuse pontine glioma that has not yet been treated with any therapy other than surgery or steroids.
  • No more than 30 days may have passed since diagnosis or surgery and entry into the study.
  • This study is open to patients age 21 and younger.

For more information and to inquire about eligibility for this study, please contact Dr. Stephen W. Gilheeney at 212-639-3973.





Disease Status

Newly Diagnosed